Neil Woodford just bought a dividend stock you’ve likely never heard of

A new stock Neil Woodford’s just bought and an old favourite look great value right now, says G A Chester.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The big story from the FTSE 100 this week is the spectacular crash of sub-prime lender Provident Financial. With Neil Woodford owning 19% of the company — and publishing a defiant blog post on his investment — his recent buys and interesting views on other stocks have been rather cast into the shadows.

For example, he’s bought more shares in his top holding AstraZeneca and continued to build his stake in Lloyds for his Income Focus fund. The Black Horse is now his third-largest holding with a weighting of 3.9%.

However, I’m particularly interested in two other Woodford stocks that I happen to agree look great buys right now. One is a familiar blue-chip giant, whose shares he believes “have not looked as attractive as they are currently, for several years.” The other is a dividend stock you’ve probably never heard of that he’s just bought a 17% stake in.

Seriously undervalued

Woodford has held tobacco companies for decades but believes the “valuation opportunity” he identified all those years ago has now “largely played out.” With one exception. He continues to see Imperial Brands (LSE: IMB) — his last remaining holding in the sector — as seriously undervalued.

The company’s shares are currently trading at around 3,200p, which is a 22% discount to their all-time high of 4,130p achieved this time last year. As Woodford has pointed out, Imperial remains a highly cash generative business with a strong dividend-growth record. The decline in the shares has put it on an undemanding price-to-earnings (P/E) ratio of 11.8 with a smokin’ dividend yield of 5.4%.

Investor sentiment towards the industry hasn’t been helped by regulatory changes to address issues of addiction proposed last month by the US Food and Drug Administration. However, Woodford and his team argue that this could ultimately be beneficial to Imperial: “We see this as the beginning of a process to deregulate next-generation products.”

New buy

I spent yesterday evening reading the AIM admission document of Global Yachting Group — now GYG (LSE: GYG) — which listed on 5 July with a placing at 100p a share. I have to say, I like the cut of its jib.

This week’s update from Woodford’s Income Focus fund revealed: “We added a new stock to the portfolio when we participated in the initial public offering of GYG. It is a cash generative business, which is expected to pay an attractive dividend and support a progressive dividend policy going forward.”

Super-rich potential

GYG is a leading super-yacht painting, supply and maintenance company with a 17% share of the global market. Its experienced management team is looking to grow the business organically and has also identified a number of potential targets for strategic acquisitions that would complement the group’s existing offering.

The board intends to pay a current-year dividend yielding 3.2% on the IPO price. This is pro rata from the listing date based on an annualised yield of 6.4%. The shares are now trading at 117.5p (market cap £55m), so we’re looking at a yield of 2.7%, rising to 5.4%+ next year. The handsome dividend is supported by forecast earnings of 9p a share, rising to 11.2p, which gives an attractive P/E progression of 13.1 down to 10.5.

Finally, the balance sheet is decent, with the IPO having reduced net gearing of 93% at the last year-end to 38% on a pro forma basis.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

G A Chester has no position in any shares mentioned. The Motley Fool UK has recommended AstraZeneca, Imperial Brands, and Lloyds Banking Group. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes

More on Investing Articles

Person holding magnifying glass over important document, reading the small print
Investing Articles

Just released: our top 3 small-cap stocks to consider buying in October [PREMIUM PICKS]

Small-cap shares tend to be more volatile than larger companies, so we suggest investors should look to build up a…

Read more »

Investing Articles

How I’d use an empty Stocks and Shares ISA to aim for a £1,000 monthly passive income

Here's how using a Stocks and Shares ISA really could help those of us who plan to invest for an…

Read more »

Investing Articles

This FTSE stock is up 20% and set for its best day ever! Time to buy?

This Fool takes a look at the half-year results from Burberry (LON:BRBY) to see if the struggling FTSE stock might…

Read more »

Investing Articles

This latest FTSE 100 dip could be an unmissable opportunity to pick up cut-price stocks

The FTSE 100 has pulled back with the government’s policy choices creating some negative sentiment. But this gives us a…

Read more »

A young woman sitting on a couch looking at a book in a quiet library space.
Investing Articles

As the WH Smith share price falls 4% on annual results, is it still worth considering?

WH Smith took a hit after this morning’s results left shareholders unimpressed. With the share price down 4%, Mark Hartley…

Read more »

Investing Articles

The Aviva share price just jumped 4.5% but still yields 7.02%! Time to buy?

A positive set of results has put fresh life into the Aviva share price. Harvey Jones says it offers bags…

Read more »

Investing Articles

Can a €500m buyback kickstart the Vodafone share price?

The Vodafone share price has been a loser for investors in recent years, and the dividend has been cut. We…

Read more »

Frustrated young white male looking disconsolate while sat on his sofa holding a beer
Growth Shares

3 mistakes I now avoid when choosing which growth stocks to buy

Jon Smith runs through some of the lessons he's learnt the hard way over the years about what to look…

Read more »